After Gilead announced in early April that it would change its patient assistance program reimbursement policy starting in October, an outcry followed, prompting the companyAlso in April, multiple generic versions of Truvada entered the market for the first time. Some have a list price as low as $30 per month, posing a major threat to Gilead’s highly profitable PrEP sales.
NBC News asked nearly 120 HIV prevention-focused 340B clinics for their PrEP-patient figures. The vast majority were unresponsive or refused to share their data. Many said they were wary of alienating Gilead, given the clinics’ further dependency on charitable grants from the company, which is the dominant manufacturer of HIV-treatment pharmaceuticals.
During an April 8 call between HIV advocates and Gilead to discuss the impending financial changes, Eric Leue, vice president of prevention services at the HIV-prevention clinic
The Afghan Nation is united and with one voice will set arround the Pakistan embassies and counslates in Afghanistan and around the world. Do similar actions what they did in Pakistan with Afghan diplomates. Wrapped them with their famlies. Took off their clothes & let them dance
Status4NorthAndEastSyria
Fun fact: the research into PrEP was funded by tax dollars, but Gilead makes all the money from it.
Clearly it’s no big deal since you can legally spread it in California
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.